Valley Grande Manor: Medication Storage Violations - TX
The facility's assistant director of nursing said the same thing, in almost the same words, during an interview with inspectors on the evening of January 30, 2026. The director of nursing, when she pulled up the order on her computer screen and read it aloud, said the Alzheimer's diagnosis was acceptable because the resident had arrived from a hospital with the order already written.
Nobody had changed it.
The resident, identified in inspection records only as Resident 1, was a man admitted to Valley Grande Manor on a date redacted from the public record. He had two diagnoses: Alzheimer's disease and vascular dementia, a condition caused by reduced blood flow to the brain that damages or kills brain cells. His cognitive assessment, completed in early January 2026, gave him a BIMS score of 3, which placed him in the category of severely impaired cognition. He could not advocate for himself, question his medications, or ask why he was receiving a drug that two of the facility's own clinical staff would later describe as potentially fatal for someone with his condition.
The drug in question, olanzapine, is an atypical antipsychotic. It carries a black box warning from the Food and Drug Administration for use in elderly patients with dementia-related psychosis. The FDA added that warning after studies showed the drug increased the risk of death in that population. Valley Grande Manor's pharmacist, reached by phone the afternoon of the inspection, was direct: Alzheimer's disease alone was not a valid indication for an antipsychotic. The pharmacist did not hedge.
The facility's own policy, last revised in December 2016, stated that antipsychotic medications could be considered for residents with dementia only after medical, physical, functional, psychological, emotional, psychiatric, social, and environmental causes of behavioral symptoms had been identified and addressed. The order in Resident 1's chart listed no behavioral symptoms. It listed no alternative approaches that had been tried and failed. The indication was simply: Alzheimer's disease, unspecified.
Resident 1 had been receiving the medication at least since December 31, 2025, when side effect monitoring and behavior monitoring orders were entered into the system. The physician's order, dated January 1, 2026, called for one 10-milligram tablet by mouth twice a day. There was no end date on the order. Medication administration records showed the drug was given throughout the first week of January 2026.
The facility's care plan, also dated January 1, listed the antipsychotic as related to Alzheimer's disease and called for monitoring side effects and effectiveness every shift. Staff were supposed to document and report adverse reactions. What the care plan did not contain was a documented clinical rationale for why the drug was necessary in the first place, or what specific symptoms it was meant to address, or what had been tried before reaching for a medication the FDA had flagged as potentially lethal in this exact patient population.
When inspectors interviewed the assistant director of nursing at just after 6 p.m. on January 30, she did not defend the prescription. She said the negative outcome of ordering an antipsychotic for a resident with Alzheimer's or dementia could be death. She said that was why it was not recommended. She said this about a medication her facility had been administering to a severely cognitively impaired man for at least a month.
The director of nursing, interviewed nearly two hours later, offered the hospital explanation. The order had come with the resident. That was the reasoning. There is no indication in the inspection record that anyone at the facility, upon receiving that order, had reviewed it against the resident's diagnoses, consulted the pharmacist, convened a care conference, or documented a clinical justification for continuing it. The order came in. The pills went out.
Olanzapine is not without legitimate uses. It is prescribed for schizophrenia and bipolar disorder, conditions involving psychosis where the drug's mechanism, blocking dopamine and serotonin receptors, addresses the underlying pathology. Alzheimer's disease is not one of those conditions. When the drug is given to elderly dementia patients, the risks include sedation, falls, stroke, and death. The FDA's black box warning on this class of drugs for elderly dementia patients has been in place for two decades.
The facility's pharmacist did not say any of this was complicated or ambiguous. Alzheimer's disease was not an appropriate diagnosis for an antipsychotic medication. That was the statement, given to inspectors at 1 p.m. on January 30. Six hours later, the facility's own assistant director of nursing agreed with it.
Federal inspectors classified the violation as a chemical restraint, a category that applies when a drug is used not to treat a specific medical symptom but in a way that limits or controls a resident's behavior without a valid clinical justification. The level of harm was cited as minimal harm or potential for actual harm. The inspection was a complaint survey, meaning someone had flagged a concern about this facility before inspectors arrived.
Valley Grande Manor is located at 1212 South Bridge Street in Weslaco, in Hidalgo County in the Rio Grande Valley. The January 30 inspection examined three residents for unnecessary medications. Inspectors found the problem in one of them.
The resident whose chart contained the order, the man with Alzheimer's disease and a BIMS score of 3, had no ability to tell anyone how the medication made him feel, whether it was helping, or whether he wanted to keep taking it. His care plan said staff would monitor him every shift. His physician's order had no end date. And when the facility's pharmacist and two senior nursing leaders were asked directly about the appropriateness of the prescription, all three said versions of the same thing: this drug, for this diagnosis, could kill him.
The record does not indicate whether the order was discontinued after the inspection.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Valley Grande Manor from 2026-01-30 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: August 4, 2026 · Our methodology
Valley Grande Manor in Weslaco, TX was cited for violations during a health inspection on January 30, 2026.
The resident, identified in inspection records only as Resident 1, was a man admitted to Valley Grande Manor on a date redacted from the public record.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.